Barclay “Buck” Phillips

Portrait Buck Phillips
Lead Independent Director

Barclay “Buck” Phillips

Buck Phillips has served as Chief Operating Officer and Chief Financial Officer of Ribometrix, Inc., a discovery stage biotechnology company developing RNA-targeted small molecule therapeutics, since August 2020. Mr. Phillips brings 30 years of experience in the biotechnology industry.

From 2008 to 2019, he served as the Chief Financial Officer for three separate Nasdaq listed, development stage biotechnology companies; G1 Therapeutics, Inc. (GTHX), Novavax, Inc. (NVAX) and Micromet, Inc. (acquired by Amgen in 2012 for $1.2B). In addition to his role as Chief Financial Officer, Mr. Phillips also held the title of SVP Corporate Development at G1 Therapeutics. During this tenure, Mr. Phillips was responsible for all finance and accounting functions, financing strategy (successfully raising over $1.4B), Wall Street and investor relations, public relations and corporate strategy, and corporate development.

Mr. Phillips also has extensive experience in life science venture and public market investing, having spent just under a decade as a Managing Director of Vector Fund Management, a late-stage life sciences venture capital fund with over $250 million in committed capital and approximately 30 venture investments in biotechnology, medical technology and healthcare services companies. In addition, Mr. Phillips was Biotechnology Analyst and Director of Venture Investments for INVESCO Funds group, a no-load mutual fund family with a healthcare sector fund franchise totaling over $3.5 billion in assets under management.

Mr. Phillips has served on the boards of several public and private companies, including roles as Audit Chair and Chair of the Nominating and Corporate Governance committees. He received a Bachelor of Arts degree in economics from the University of Colorado at Boulder.

Mr. Phillips has been a member of Immunic’s Board since November 2019. He is chairman of the Audit Committee and a member of the Nominating and Corporate Governance Committee.

Back to Team Members